ACE, PAI-1, decorin and Werner helicase genes are not associated with the development of renal disease in European patients with Type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 15, Issue 4, 1999, Pages 247-253

  De Cosmo, S ^a   Margaglione, M ^a   Tassi, V ^a   Garrubba, M ^a   Thomas, S ^b   Olivetti, C ^c   Piras, G P ^d   Trevisan, R ^e   Vedovato, M ^e   Cavallo Perin, P ^c   Bacci, S ^a   Colaizzo, D ^a   Cisternino, C ^a   Zucaro, L ^a   Di Minno, G ^a   Trischitta, V ^a   Viberti, G C ^a,b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b GUY S HOSPITAL   (United Kingdom)

^c Institute of Internal Medicine   (Italy)

^d BROTZU HOSPITAL   (Italy)

^e Department of Metabolic Medicine ^*  (Italy)

Author keywords

Albuminuria; Diabetic nephropathy; Gene polymorphism; Type 1 diabetes

Indexed keywords

DECORIN; DIPEPTIDYL CARBOXYPEPTIDASE; HELICASE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; PRIORITY JOURNAL; PROTEINURIA; WERNER SYNDROME;

ADULT; ALLELES; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DNA HELICASES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENOTYPE; GREAT BRITAIN; HUMANS; ITALY; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEOGLYCANS; RECQ HELICASES; WERNER SYNDROME;

EID: 0032832439     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-7560(199907/08)15:4<247::AID-DMRR41>3.0.CO;2-P     Document Type: Article

References (48)

1. Andersen AR, Christiansen JS, Andersen JK, Kreiner JK, Deckert T. Diabetic nephropathy in type I (insulin dependent) diabetes: an epidemiological study. Diabetologia 1983; 25: 496-501.
2. Krolewski AS, Laffel L, Krolewski M, et al. Glycosilated haemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251-1255.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus. New Engl J Med 1993; 329: 977-986.
4. Microalbuminuria Collaborative Study Group. Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ 1993; 306: 1235-1259.
5. Viberti GC, Mogensen CE, Groop L, Paulus JF, European Microalbuminuria Captopril Study Group. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes and microalbuminuria. JAMA 1994; 271: 275-279.
6. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med 1989; 320: 1161-1165.
7. Borch-Johnsen K, Norgaard K, Hommel E, et al. Is diabetic nephropathy an inherited complication? Kidney Int 1992; 41: 719-722.
8. Marre M, Bernadet P, Gallois Y, et al. Relationship between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994: 43: 384-388.
9. Tarnow L, Cambien F, Rossing P, et al. Lack of relationship between an insertion/deletion polymorphism in the angiotensin 1-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes 1995; 44: 489-495.
10. Fujisawa T, Ikegami H, Kawaguchi Y, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia 1998; 41: 47-53.
11. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86: 1343-1346.
12. Cambien F, Poirer O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-644.
13. Tiret L, Kee F, Poirer O, et al. Deletion polymorphism in angiotensin-converting enzyme gene associated with parental history of myocardial infarction. Lancet 1993; 341: 991-992.
14. Tarnow L, Cambien F, Rossing P, et al. Insertion/deletion polymorphism in the angiotensin-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia 1995; 38: 798-803.
15. Lindpaintner K, Pfeffer MA, Kreutz R, et al. A prospective evaluation of an angiotensin-converting enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med 1995; 322: 706-711.
16. Ruiz J, Blanche H, Cohen N, et al. Insertion/deletion polymorphism of the angiotensin-converting enzyme gene is strongly associated with coronary heart disease in non-insulin dependent diabetes mellitus. Proc Natl Acad Sci USA 1994; 91: 3662-3665.
17. Parving HH, Tarnow L, Rossing P. Genetics of diabetic nephropathy. J Am Soc Nephrol 1996; 7: 2509-2517.
18. Tarnow L, Gluud C, Parving H-H. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrol Dial Transplant 1998; 13: 1125-1130.
19. Gray RP, Patterson DL, Yudkin JS. Plasminogen activator inhibitor activity in diabetic and non diabetic survivors of myocardial infarction. Arterioscler Thromb 1993; 13: 415-420.
20. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
21. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin dependent diabetes. Thromb Haemost 1995; 74: 1032-1034.
22. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with alterated levels of plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-190.
23. Hirano T, Kashiwazaki K, Moritomo Y, Nagano S, Adachi M. Albuminuria is directly associated with increased plasma PAI-1 and factor VII levels in NIDDM patients. Diabetes Res Clin Pract 1997; 36: 11-18.
24. Deckert T, Yokoyama H, Mathiensen E, et al. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ 1996; 312: 871-874.
25. De Cosmo S, Bacci S, Piras GP, et al. High prevalence of risk factor for cardiovascular disease in parents of IDDM patients with albuminuria. Diabetologia 1997; 40: 1191-1196.
26. Earle K, Walker J, Hill C, Viberti GC. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992; 326: 673-677.
27. Osterby R, Parving H-H, Hommel E, Jorgensen HE, Lokkergard H. Glomerular structure and function in diabetic nephropathy: early to advanced stages. Diabetes 1990; 39: 1057-1063.
28. Yamamoto T, Nakamura T, Noble NA, Rouslahti E, Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818.
29. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor by the proteoglycan decorin. Nature 1990; 346: 281-282.
30. Jensen T. Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes 1997; 46 (Suppl 2): S98-S100.
31. Briggs MD, Cohn DH. Length polymorphism within a complex dinucleotide repeat in the human decorin (DCN) gene. Hum Mol Genet 1993; 2: 1087.
32. Morocutti A, Earle KA, Sethi M, et al. Premature senescence of skin fibroblasts from insulin-dependent diabetic patients with kidney disease. Kidney Int 1996; 50: 250-256.
33. Martin GM, Sprague CA, Epstein CJ. Replicative life-span of cultiveted human cells. Lab Invest 1970; 23: 86-92.
34. Epstein CJ, Martin G, Schultz AL, Motulsky AG. Werner's syndrome: a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine 1966; 45: 177-222.
35. Matsumoto T, Imamura O, Yamabe Y, et al. Mutation and haplotype analyses of the Werner's syndrome gene based on its genomic structure: genetic epidemiology in the Japanese population. Human Genet 1997; 100: 123-130.
36. Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner's syndrome gene. Science 1996; 272: 258-262.
37. Ye L, Miki T, Nakura J, et al. Association of a polymorphic variant of the Werner helicase gene with myocardial infarction in a Japanese population. Am J Med Genet 1997; 68: 494-498.
38. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: a Laboratory Manual (2nd edn). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
39. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (Dipeptyl carboxypeptidase 1). Nucleic Acid Res 1992; 20: 1433.
40. Margaglione M, Celentano E, Grandone E, et al. Deletion polymorphism of the angiotensin converting enzyme gene in patients with a history of ischaemic stroke. Arterioscler Thromb Vasc Biol 1996; 16: 304-309.
41. Margaglione M, Grandone E, Cappucci G, et al. An alternative method for PAI-1 promoter polymorphism (4G/5G) typing. Thromb Haemost 1997; 77: 605-606.
42. Chowdhury TA, Dronsfield MJ, Kumar S, et al. Examination of two genetic polymorphism within the renin-angiotensin system: no evidence for an association with nephropathy in IDDM. Diabetologia 1996; 39: 1108-1114.
43. Margaglione M, Cappucci G, d'Addetta M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerotis: relation to enviromental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18: 562-567.
44. Walker JD, Close CF, Jones SL, et al. Glomerular structure in type 1 (insulin-dependent) diabetic patients with normo and microalbuminuria. Kidney Int 1992; 41: 741-748.
45. Parving H-H, Hommel E, Mathiensen E, et al. Prevalence of microalbuiminuria, arterial hypertension and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988; 296: 156-160.
46. Schmitd S, Schone N, Ritz E, et al. Association of ACE genen polymorphism and diabetic nephropathy?. The diabetic Nephropathy Study Group. Kidney Int 1995; 47: 1176-1181.
47. Ringel J, Beige J, Kunz R, et al. Genetic variation of the renin-angiotensin system, diabetic nephropathy and hypertension. Diabetologia 1997; 40: 193-199.
48. Marre M, Jeunemaitre X, Gallois Y, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 1997; 99: 1585-1595.